StockData
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. (FULC) stock

FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.72−0.03 (-0.80%)

Close on Nov 18, 2026Market cap $283.83MP/E –Yield –

Fulcrum Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Fulcrum Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$96.05M. For fiscal 2025 it was -$84.77M. The highest annual figure on record is -$21.90M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$84.77M–
FY2024Dec 31, 2024-$21.90M–
FY2023Dec 31, 2023-$110.66M–
FY2022Dec 31, 2022-$112.56M–
FY2021Dec 31, 2021-$81.05M–
FY2020Dec 31, 2020-$71.61M–
FY2019Dec 31, 2019-$84.22M–
FY2018Dec 31, 2018-$33.50M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$29.31M–
Q1 FY2026Mar 31, 2026-$22.19M–
Q4 FY2025Dec 31, 2025-$22.69M–
Q3 FY2025Sep 30, 2025-$21.86M–
Q2 FY2025Jun 30, 2025-$19.82M-137.7%
Q1 FY2025Mar 31, 2025-$20.40M–
Q4 FY2024Dec 31, 2024-$19.43M–
Q3 FY2024Sep 30, 2024-$25.13M–
Q2 FY2024Jun 30, 2024$52.49M–
Q1 FY2024Mar 31, 2024-$29.83M–
Q4 FY2023Dec 31, 2023-$27.99M–
Q3 FY2023Sep 30, 2023-$27.44M–
Q2 FY2023Jun 30, 2023-$27.29M–
Q1 FY2023Mar 31, 2023-$27.94M–
Q4 FY2022Dec 31, 2022-$27.97M–
Q3 FY2022Sep 30, 2022-$24.36M–
Q2 FY2022Jun 30, 2022-$34.24M–
Q1 FY2022Mar 31, 2022-$26.00M–
Q4 FY2021Dec 31, 2021-$23.56M–
Q3 FY2021Sep 30, 2021-$20.77M–
Q2 FY2021Jun 30, 2021-$19.68M–
Q1 FY2021Mar 31, 2021-$17.04M–
Q4 FY2020Dec 31, 2020-$17.79M–
Q3 FY2020Sep 30, 2020-$19.10M–
Q2 FY2020Jun 30, 2020-$15.92M–
Q1 FY2020Mar 31, 2020-$18.80M–
Q4 FY2019Dec 31, 2019-$16.49M–
Q3 FY2019Sep 30, 2019-$17.01M–
Q2 FY2019Jun 30, 2019-$13.49M–
Q1 FY2019Mar 31, 2019-$37.23M–
Q4 FY2018Dec 31, 2018-$9.25M–
Q3 FY2018Sep 30, 2018-$9.09M–
Q2 FY2018Jun 30, 2018-$7.85M–

More Fulcrum Therapeutics figures

See a number that looks wrong?